News >

Hormonal Maintenance Therapy Improves PFS in Low-Grade Serous Ovarian Cancer

Danielle Bucco
Published: Thursday, Mar 16, 2017

David M. Gershenson, MD

David M. Gershenson, MD

Women with stage II to IV low-grade serous carcinoma of the ovary or peritoneum who received hormonal maintenance therapy after primary treatment had significantly longer progression-free survival (PFS) compared with women who underwent routine observation, according to a retrospective database study published in the Journal of Clinical Oncology.

In his interview, Gershenson, a professor of gynecologic oncology at The University of Texas MD Anderson Cancer Center, discusses the results for the retrospective study and the next steps going forward.

OncLive: Can you provide an overview of the study?

Gershenson: This is a retrospective database study of women who have this rare subtype of ovarian cancer. We analyzed a total of 203 women, 133 of whom had been treated with primary cytoreductive surgery for stage II, III, or IV, low-grade serous carcinoma, followed by platinum-based chemotherapy and then surveillance. We compared that to 70 women who had the same treatment surgery followed by platinum-based chemotherapy, but were then placed on hormonal maintenance therapy with one of the antiestrogens that are used for breast cancer, such as aromatase inhibitors or tamoxifen.

I think the main message of this study was that there was a very significant difference in PFS that favored the women who received a hormonal maintenance therapy and we believe that it is potentially practice changing. We're in the process of trying to develop a randomized clinical trial to confirm our findings.

What are the next steps regarding this study?

We work through NRG Oncology, which is an NCI-sponsored cooperative group and we are trying to partner with international colleagues. The study that is in development is a randomized phase III study that would take the same patients with stage II, III, or IV low-grade serous carcinoma of the ovary or peritoneum. They would all undergo primary cytoreductive surgery followed by platinum-based chemotherapy and that generally would be carboplatin and paclitaxel although there are some variations on that theme.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication
x